Dupilumab significantly improves atopic dermatitis in children aged 6-11 years: results from a phase III trial (LIBERTY AD PEDS)

被引：0
作者：
Paller, A. S. [1 ]
Siegfried, E. C. [2 ,3 ]
Gooderham, M. [4 ,5 ]
Beck, L. A. [6 ]
Boguniewicz, M. [7 ,8 ]
Sher, L. [9 ]
Weisman, J. [10 ]
Staudinger, H. W. [11 ]
Sun, X. [12 ]
Shumel, B. [12 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] St Louis Univ, St Louis, MO 63103 USA
[3] Cardinal Glennon Childrens Hosp, St Louis, MO USA
[4] SKiN Ctr Dermatol, Peterborough, ON, Canada
[5] Queens Univ, Kingston, ON, Canada
[6] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[7] Natl Jewish Hlth, Denver, CO USA
[8] Univ Colorado, Sch Med, Denver, CO USA
[9] Peninsula Res Associates, Rolling Hills Estates, CA USA
[10] Adv Med Res PC, Atlanta, GA USA
[11] Sanofi, Cambridge, MA USA
[12] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2020年 / 183卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P50
引用
收藏
页码：E121 / E121
页数：1
相关论文
共 50 条
  • [31] Dupilumab improves signs and symptoms of severe atopic dermatitis in children aged 6e11 years with and without comorbid asthma
    Boguniewicz, Mark
    Sher, Lawrence
    Paller, Amy S.
    Siegfried, Elaine C.
    Soong, Weily
    Chen, Zhen
    Prescilla, Randy
    Shumel, Brad
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB141 - AB141
  • [32] Pharmacokinetics, safety and efficacy of dupilumab in children aged ≥ 2 to < 6 years with severe, uncontrolled atopic dermatitis (LIBERTY AD PRE-SCHOOL)
    Simpson, E. L.
    Lockshin, B.
    Kamal, M.
    Davis, J. D.
    Sun, X.
    Gadkari, A.
    Rossi, A. B.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E95 - E96
  • [33] Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)
    Wollenberg, A.
    Beck, L. A.
    Blauvelt, A.
    Simpson, E. L.
    Chen, Z.
    Chen, Q.
    Shumel, B.
    Khokhar, F. A.
    Hultsch, T.
    Rizova, E.
    Rossi, A. B.
    Graham, N. M. H.
    Pirozzi, G.
    Lu, Y.
    Ardeleanu, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (05) : 1120 - 1135
  • [34] Pharmacokinetics, safety, and efficacy of dupilumab in children aged ≥2 to <6 years with severe uncontrolled atopic dermatitis (LIBERTY AD PRE-SCHOOL)
    Simpson, Eric L.
    Kamal, Mohamed Ahmed
    Davis, John D.
    Sun, Xian
    Gadkari, Abhijit
    Eckert, Laurent
    Rossi, Ana Beatris
    Bansal, Ashish
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB19 - AB19
  • [35] Dupilumab treatment leads to mild transient increases in eosinophil levels without clinical relevance in children aged 6-11 years with severe atopic dermatitis
    Paller, Amy
    Wollenberg, Andreas
    Cork, Michael
    Siegfried, Elaine
    Chen, Zhen
    Vakil, Jignesh
    Levit, Noah
    Marco, Ainara Rodriguez
    Radwan, Amr
    CLINICAL AND EXPERIMENTAL ALLERGY, 2021, 51 (12) : 1687 - 1688
  • [36] Dupilumab rapidly improves atopic dermatitis symptoms in children aged ≥ 6 to < 12 years as measured by POEM
    Silverberg, J. I.
    Eichenfield, L. F.
    Wollenberg, A.
    Praestgaard, A.
    Delevry, D.
    Rossi, A. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E119 - E119
  • [37] Dupilumab Treatment in Children Aged 6–11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study
    Maddalena Napolitano
    Gabriella Fabbrocini
    Iria Neri
    Luca Stingeni
    Valeria Boccaletti
    Vincenzo Piccolo
    Giuseppe Fabrizio Amoruso
    Giovanna Malara
    Rocco De Pasquale
    Eugenia Veronica Di Brizzi
    Laura Diluvio
    Luca Bianchi
    Andrea Chiricozzi
    Adriana Di Guida
    Elisabetta Del Duca
    Viviana Moschese
    Vito Di Lernia
    Federica Dragoni
    Michaela Gruber
    Katharina Hansel
    Amelia Licari
    Sara Manti
    Salvatore Leonardi
    Luca Mastorino
    Michela Ortoncelli
    Eugenio Provenzano
    Antonino Palermo
    Vincenzo Patella
    Tiziana Peduto
    Elena Pezzolo
    Viviana Piras
    Luca Potestio
    Teresa Battista
    Rosanna Satta
    Stefania Termine
    Paolo Palma
    Paola Zangari
    Cataldo Patruno
    Pediatric Drugs, 2022, 24 : 671 - 678
  • [38] Dupilumab Treatment for 16 Weeks Reported Mild Increases in Eosinophil Levels Without Clinical Relevance in Children Aged 6-11 Years with Severe Atopic Dermatitis
    Paller, Amy S.
    Wollenberg, Andreas
    Cork, Michael
    Siegfried, Elaine
    Chen, Zhen
    Khokhar, Faisal
    Levit, Noah
    Marco, Ainara Rodriguez
    PEDIATRICS, 2022, 149 (01)
  • [39] Dupilumab provides improvement in sleep in children aged ≥ 6 years with severe atopic dermatitis (AD) and adolescents with moderate-to-severe AD
    Paller, A.
    Wollenberg, A.
    Simpson, E.
    Beck, L.
    Hong, C-H
    Marcoux, D.
    Chen, Z.
    Levit, N.
    Bansal, A.
    Rossi, A.
    Chao, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 : 57 - 58
  • [40] Dupilumab Efficacy in Children With Atopic Dermatitis Aged 6 Months to 5 Years With and Without Atopic Comorbidities
    Boguniewicz, Mark
    Sher, Lawrence
    Paller, Amy
    Chen, Zhen
    Shah, Parul
    Rodriguez-Marco, Ainara
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB148 - AB148
12345